SLC39A1 Antibody

What is SLC39A1 and what is its biological function?

SLC39A1 (Solute Carrier Family 39 Member 1), also known as ZIP1, is a zinc ion transport protein localized to the plasma membrane. It functions as the major importer of zinc from circulating blood plasma into cells, facilitating the influx of Zn²⁺ from extracellular space .

SLC39A1 plays pivotal roles in:

• Maintaining cellular zinc homeostasis

• Supporting immune function, growth, and development

• Mediating the rapid uptake and accumulation of physiologically effective zinc in cells, particularly in prostate cells

The protein consists of 324 amino acids and belongs to the zinc-iron permease family. As the first member of the SLC39 family, SLC39A1 is widely distributed across various tissue cells .

What types of SLC39A1 antibodies are available for research applications?

Researchers can access multiple types of SLC39A1 antibodies optimized for different experimental approaches:

Most commercially available antibodies target epitopes in the extracellular domain of SLC39A1, with some specifically recognizing the N-terminal region .

How do I determine which SLC39A1 antibody is most suitable for my experimental design?

When selecting an SLC39A1 antibody, consider these key factors:

• Experimental application: Different antibodies perform optimally in specific applications:

  • For protein expression studies: Choose antibodies validated for Western blot

  • For localization studies: Select antibodies validated for IHC or ICC/IF

  • For flow cytometry: Use antibodies specifically validated for FACS

• Species reactivity: Ensure the antibody recognizes SLC39A1 in your experimental model organism. Available antibodies react with human, mouse, and rat SLC39A1, with varying degrees of cross-reactivity .

• Epitope location: Consider whether you need to detect:

  • Full-length protein (324 amino acids)

  • Specific domains (extracellular vs. transmembrane)

  • Post-translationally modified forms

• Validation data: Review published literature citing the antibody's use in applications similar to yours to gauge reliability and specificity .

What are the optimal conditions for using SLC39A1 antibodies in Western blot analysis?

For optimal Western blot results with SLC39A1 antibodies:

Sample preparation:

• Use fresh tissue lysates or cell lines known to express SLC39A1 (U87 glioblastoma, MDA-231 breast adenocarcinoma, and prostate cell lines are well-documented )

• Standard RIPA buffer with protease inhibitors is suitable for extraction

• Use 15-25 μg of total protein per lane

Technical parameters:

• Predicted molecular weight: ~34 kDa (may vary based on post-translational modifications)

• Recommended antibody dilutions: 1:200-1:1000 (optimize based on specific antibody)

• Blocking: 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Primary antibody incubation: Overnight at 4°C

Controls:

• Positive control: Mouse kidney tissue lysate consistently shows good detection

• Negative control: Include a pre-adsorption control using SLC39A1 blocking peptide to confirm specificity

Troubleshooting tip: If detecting multiple bands, this may reflect isoforms, as at least two isoforms of ZIP1 are known to exist .

How can I effectively use SLC39A1 antibodies for immunohistochemistry in cancer tissues?

For successful IHC detection of SLC39A1 in cancer tissues:

Sample preparation:

• Both frozen sections and FFPE (formalin-fixed paraffin-embedded) tissues are suitable

• For FFPE tissues, antigen retrieval is critical (typically citrate buffer pH 6.0, heat-induced)

• Section thickness: 4-6 μm is optimal

Protocol optimization:

• Deparaffinize and rehydrate sections (for FFPE)

• Perform antigen retrieval

• Block endogenous peroxidase (3% H₂O₂) and non-specific binding (5-10% normal serum)

• Apply primary SLC39A1 antibody (typically 1:200-1:400 dilution)

• Detect with appropriate secondary antibody and visualization system

• Counterstain, dehydrate, and mount

Scoring methods:
For clinical correlation studies, use standardized scoring systems:

• Semi-quantitative scoring: Combine intensity (0-3) and percentage of positive cells

• H-score method: ∑(intensity × percentage of positive cells), range 0-300

• Computer-assisted image analysis for objective quantification

This approach has been successfully used to correlate SLC39A1 expression with clinical parameters in hepatocellular carcinoma and glioma studies .

What cell lines are most appropriate for studying SLC39A1 function in cancer research?

Based on the literature, these cell lines are well-established for SLC39A1 research:

When using these cell lines:

• Confirm endogenous SLC39A1 expression before experimental manipulation

• Consider both knockdown (siRNA) and overexpression approaches, as both have been successfully used to demonstrate SLC39A1 function

• For functional studies, analyze effects on proliferation (CCK-8 assay), apoptosis (flow cytometry), and expression of downstream targets like MMP2/MMP9

How do I interpret contradictory findings regarding SLC39A1 expression in different cancer types?

The literature reveals opposing patterns of SLC39A1 expression and function across cancer types:

To accurately interpret these contradictions:

• Consider tissue-specific function: The baseline zinc requirements and homeostatic mechanisms differ between tissues, explaining why altered SLC39A1 has different effects.

• Assess methodological differences: Studies use various techniques (IHC, RT-qPCR, Western blot) with different antibodies, potentially explaining discrepancies.

• Evaluate contextual factors:

  • The role of zinc in each cancer microenvironment varies

  • Disease stage at assessment may differ between studies

  • Additional genetic alterations may modify SLC39A1's impact

• Design validation experiments: When encountering contradictory findings, replicate key experiments using multiple detection methods and include appropriate controls.

What are the key signaling pathways associated with SLC39A1 function that can be studied using antibody-based approaches?

SLC39A1 influences multiple signaling pathways that can be investigated using antibody-based methods:

• Wnt/β-catenin Signaling Pathway:

  • SLC39A1 overexpression has been linked to activation of Wnt signaling pathway

  • Key proteins to detect: Wnt3A, β-catenin, cyclin D1

  • Methodology: Western blot to detect total and activated (non-phosphorylated) β-catenin levels

• MMP2/MMP9 Expression:

  • SLC39A1 significantly influences MMP2/MMP9 expression

  • Methodology: Western blot, gelatin zymography, RT-qPCR to measure both expression and activity

  • Relevant antibodies: Anti-MMP2, anti-MMP9, anti-TIMP (tissue inhibitors of metalloproteinases)

• Immune Infiltration Pathways:

  • SLC39A1 expression correlates with immune cell infiltration in the tumor microenvironment

  • Gene enrichment analysis shows association with:

    • Extracellular matrix organization

    • Neutrophil activation

    • Leukocyte migration

    • Antigen processing and presentation

  • Methodology: Multiplex immunofluorescence with immune cell markers (CD4, CD8, macrophage markers)

• TNF Signaling Pathway:

  • KEGG analysis shows SLC39A1 enrichment in TNF signaling pathway

  • Methodology: Analyze NF-κB activation (phosphorylation, nuclear translocation)

How can I reliably assess the effects of SLC39A1 knockdown or overexpression in cellular models?

For rigorous assessment of SLC39A1 manipulation:

Knockdown Approach:

• siRNA transfection:

  • Use at least 2-3 different siRNA sequences targeting different regions of SLC39A1

  • Include scrambled siRNA as negative control

  • Confirm knockdown efficiency by both RT-qPCR and Western blot (>70% reduction considered successful)

• shRNA for stable knockdown:

  • Useful for long-term studies

  • Verify knockdown stability over multiple passages

Overexpression Approach:

• Plasmid transfection:

  • Use expression vectors with strong promoters (CMV)

  • Include empty vector as control

  • Verify expression by Western blot and immunofluorescence

  • Consider epitope-tagged constructs (FLAG, HA) if antibody detection is challenging

Functional Readouts:

• Proliferation: CCK-8 assay, BrdU incorporation, colony formation

• Apoptosis: Flow cytometry analysis with Annexin V/PI staining

• Migration/Invasion: Transwell assay, wound healing assay

• Zinc uptake: Using fluorescent zinc indicators (FluoZin-3)

• Downstream target analysis: Western blot for MMP2/MMP9 expression

In vivo validation:
For comprehensive assessment, consider xenograft models with SLC39A1-manipulated cells and IHC confirmation of protein expression changes.

How can I study the relationship between SLC39A1 expression and immune infiltration in the tumor microenvironment?

To investigate SLC39A1's relationship with immune infiltration:

Bioinformatic Approaches:

• ESTIMATE algorithm analysis:

  • Calculates ImmuneScore, StromalScore, and ESTIMATEScore from RNA-seq data

  • Correlate these scores with SLC39A1 expression levels

• CIBERSORT algorithm:

  • Analyzes proportions of 22 immune cell subgroups

  • Identify specific immune cell types associated with SLC39A1 expression

  • Research shows significant positive correlation with T-regs, Macrophages M2, and negative correlation with activated NK cells

Experimental Validation:

• Multiplex immunofluorescence:

  • Co-stain tissue sections for SLC39A1 and immune cell markers

  • Markers to consider: CD68 (macrophages), CD4/FOXP3 (T-regs), CD56 (NK cells)

  • Quantify spatial relationships between SLC39A1+ cells and immune infiltrates

• Flow cytometry:

  • Analyze fresh tumor samples for both SLC39A1 expression and immune cell composition

  • Sort SLC39A1-high vs. SLC39A1-low tumor cells and assess differences in cytokine production

• Co-culture experiments:

  • Culture SLC39A1-manipulated tumor cells with immune cells

  • Measure changes in immune cell activation, cytokine production, and migration

This integrated approach has revealed that SLC39A1 expression significantly correlates with immune infiltration patterns, particularly increased macrophage M2 infiltration in gliomas .

What are the optimal methods for investigating SLC39A1's role in zinc transport and cellular zinc homeostasis?

To comprehensively study SLC39A1's zinc transport function:

Cellular Zinc Measurement:

• Fluorescent zinc probes:

  • FluoZin-3 AM (cell-permeable): Measures intracellular free zinc

  • Zinpyr-1: Alternative probe with different sensitivity range

  • Protocol: Load cells with probe (1-5 μM, 30-60 min), wash, measure fluorescence by microscopy or flow cytometry

• Inductively coupled plasma mass spectrometry (ICP-MS):

  • Gold standard for quantitative total zinc measurement

  • Requires cell digestion but provides absolute zinc concentration

  • Compare SLC39A1 knockdown/overexpression cells with controls

Zinc Transport Kinetics:

• ⁶⁵Zn uptake assays:

  • Incubate cells with radioactive zinc

  • Measure uptake over time course (5-60 minutes)

  • Compare Vmax and Km parameters between experimental groups

• Zinc chelation and add-back experiments:

  • Deplete cellular zinc with chelators (TPEN)

  • Measure kinetics of zinc recovery with/without functional SLC39A1

Localization Studies:

• Subcellular fractionation:

  • Separate membrane, cytosolic, and organelle fractions

  • Perform Western blot to detect SLC39A1 localization

  • Correlate with zinc distribution across cellular compartments

• Live-cell imaging:

  • GFP-tagged SLC39A1 expression

  • Co-localization with compartment-specific zinc probes

  • Measure dynamic changes upon zinc depletion/supplementation

These methodologies can help resolve contradictions in the literature regarding SLC39A1's role in different cancer types, where zinc requirements and homeostatic mechanisms may differ significantly.

How can I investigate the post-translational modifications and trafficking of SLC39A1 protein?

To study SLC39A1 post-translational modifications and trafficking:

Post-translational Modifications:

• Ubiquitination analysis:

  • Immunoprecipitate SLC39A1 and probe with anti-ubiquitin antibodies

  • Use proteasome inhibitors (MG132) to enhance detection of ubiquitinated forms

  • Research indicates zinc-induced ubiquitination may regulate SLC39A1 levels similar to other ZIP family proteins

• Phosphorylation studies:

  • Phospho-specific antibodies if available

  • Mass spectrometry analysis of immunoprecipitated SLC39A1

  • Phosphatase treatment to confirm modifications

• Proteolytic processing:

  • Western blot analysis under different zinc conditions

  • Detection of potential cleavage products (similar to ZIP4's ectodomain cleavage)

  • Site-directed mutagenesis of potential cleavage sites

Protein Trafficking:

• Surface biotinylation assays:

  • Label cell surface proteins with biotin

  • Pull down with streptavidin and detect SLC39A1 by Western blot

  • Monitor internalization rates under different zinc conditions

• Fluorescence-based trafficking assays:

  • Express pH-sensitive GFP-tagged SLC39A1

  • Track endocytosis and recycling through pH changes

  • Quantify surface vs. internalized pools

• Colocalization studies:

  • Immunofluorescence with markers for different cellular compartments:

    • Early endosomes (EEA1)

    • Recycling endosomes (Rab11)

    • Lysosomes (LAMP1)

    • ER (calnexin)

    • Golgi (GM130)

These approaches can help elucidate how SLC39A1 levels and activity are regulated in response to changing zinc levels and other cellular signals, providing insight into its dysregulation in cancer.

What are common issues encountered when using SLC39A1 antibodies and how can they be resolved?

Validation approaches:

• siRNA knockdown followed by antibody detection to confirm specificity

• Pre-adsorption with blocking peptide should eliminate specific signal

• Compare results with multiple antibodies targeting different epitopes

• Correlate protein detection with mRNA expression data

How can I ensure reproducibility when measuring SLC39A1 expression across different experimental platforms?

To ensure reproducible SLC39A1 detection across platforms:

For Western blot standardization:

• Use consistent protein extraction methods (same buffer composition)

• Load equal amounts of protein (15-25 μg) verified by total protein staining

• Include internal loading controls (β-actin, GAPDH)

• Use the same antibody concentration and incubation conditions

• Implement quantitative analysis with normalization to controls

For IHC/ICC standardization:

• Establish standard fixation protocol (duration, temperature)

• Use automated staining platforms when possible

• Include positive and negative controls in each batch

• Use quantitative scoring methods (H-score, digital image analysis)

• Have multiple observers score results independently

Cross-platform validation:

• Confirm key findings using multiple techniques:

  • Support Western blot results with IHC on the same samples

  • Correlate protein expression with mRNA levels (RT-qPCR, RNA-seq)

• Include reference cell lines with known SLC39A1 expression levels

• Use standardized reporting formats following ARRIVE or similar guidelines

Data management:

• Record detailed experimental conditions including antibody lot numbers

• Document all protocol variations

• Maintain raw data alongside analyzed results

• Consider public deposition of data for key findings

This systematic approach has been essential in resolving contradictory findings regarding SLC39A1's role in different cancer types .